Ripretinib did not improve progression-free survival but proved more tolerable than sunitinib.
The absolute risk for overall cancer was 4.7% during the first year of follow-up.
The study revealed no new safety signals compared with previous reports.
The median survival was significantly longer in patients who received opioid prescriptions than in those who did not.
The most common topics of tweets were early detection of disease, bereavement, and research.
There was no significant difference in survival between the TACE and non-TACE groups overall, but there were differences for prophylactic post-surgical TACE, palliative TACE, and curative TACE.
Oxaliplatin did not prolong progression-free survival and was associated with more adverse events.
Compared with patients who had a medium platelet count, patients with a very high platelet count had more than double the risk of a solid tumor diagnosis.
Early treatment discontinuation was associated with a decrease in survival, but early oxaliplatin discontinuation was not.
Adding durvalumab to gemcitabine and cisplatin improved progression-free and overall survival.
The median overall survival was 7.5 months in the eryaspase arm and 6.7 months in the chemotherapy-alone arm.
The median overall survival was 16.4 months with STRIDE and 13.8 months with sorafenib.
TACE improved responses and survival outcomes.
Patients with pancreatic ductal adenocarcinoma may have been spared the COVID-related delays in care seen for other cancers, according to researchers.
The improvement in response did not translate to a survival benefit.
Adjuvant S-1 improved survival over surgery alone.
Both platinum-based chemotherapy regimens are standard of care for digestive system neuroendocrine carcinoma.
Adding docetaxel to cisplatin and fluorouracil improved overall survival.
The updated results are from a median survival follow-up of 18.5 months and 133 overall survival events.
About 59% of patients achieved a pathologic complete response.